Bioventus Inc. $BVS Shares Sold by Renaissance Technologies LLC

Posted by Brian Himes on Aug 7th, 2026

Renaissance Technologies LLC cut its stake in shares of Bioventus Inc. (NASDAQ:BVS – Free Report) by 20.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 489,460 shares of the company’s stock after selling 125,640 shares during the quarter. Renaissance Technologies LLC owned 0.59% of Bioventus worth $4,469,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of BVS. Marshall Wace LLP boosted its position in shares of Bioventus by 0.4% in the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after purchasing an additional 1,281 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after buying an additional 1,538 shares during the period. Mercer Global Advisors Inc. ADV lifted its stake in Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock valued at $101,000 after buying an additional 1,887 shares in the last quarter. Deutsche Bank AG boosted its holdings in shares of Bioventus by 8.2% in the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after buying an additional 1,908 shares during the period. Finally, Engineers Gate Manager LP boosted its holdings in shares of Bioventus by 6.0% in the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after buying an additional 3,909 shares during the period. 62.94% of the stock is owned by institutional investors and hedge funds.

Bioventus Stock Down 8.4%

Bioventus stock opened at $13.98 on Friday. Bioventus Inc. has a twelve month low of $6.26 and a twelve month high of $15.89. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The firm has a market cap of $1.17 billion, a PE ratio of 18.16, a P/E/G ratio of 1.94 and a beta of 0.63. The firm’s 50 day moving average price is $10.70 and its two-hundred day moving average price is $9.66.

Bioventus (NASDAQ:BVS – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.22. Bioventus had a net margin of 9.36% and a return on equity of 29.77%. The company had revenue of $153.21 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, research analysts predict that Bioventus Inc. will post 0.79 EPS for the current fiscal year.

Trending Headlines about Bioventus

Here are the key news stories impacting Bioventus this week:

Positive Sentiment: Bioventus reported second-quarter revenue of $153.2 million, up 4% year over year, while adjusted EPS rose to $0.22 from $0.21 and matched analyst expectations. Pain Treatments revenue increased 11.5%, led by strong Durolane volume growth. Bioventus Reports Second Quarter Financial Results
Positive Sentiment: GAAP diluted EPS jumped to $0.47 from $0.11, and net income attributable to Bioventus rose to $33.4 million from $7.5 million. However, much of the GAAP improvement was related to the removal of a $24.6 million deferred-tax valuation allowance, rather than underlying operating growth. Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed
Positive Sentiment: The board disclosed an unsolicited acquisition proposal and other expressions of interest and formed an independent committee, advised by Evercore and Latham & Watkins, to evaluate options including a sale. A transaction could provide a takeover premium and is likely supporting investor interest in BVS. $600M Durham company weighs sale as stock soars
Positive Sentiment: Bioventus reaffirmed 2026 guidance for revenue of $600 million to $610 million, adjusted EPS of $0.75 to $0.79 and operating cash flow of $84 million to $89 million. It also made a $20 million term-loan prepayment, reducing debt and future interest costs. Bioventus outlines 2026 net leverage below 1.5x while board reviews strategic options
Neutral Sentiment: The strategic review has no timetable and may end with no transaction, leaving BVS exposed to deal-related volatility. Surgical Solutions revenue fell 4.5% and Restorative Therapies revenue declined 2.4%, partly offsetting Pain Treatments growth.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on BVS shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a research note on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Bioventus in a research note on Tuesday, June 2nd. Craig Hallum restated a “buy” rating and issued a $18.00 target price on shares of Bioventus in a report on Thursday. Finally, Barrington Research set a $18.00 target price on Bioventus in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, Bioventus presently has an average rating of “Buy” and an average price target of $16.25.

Get Our Latest Analysis on Bioventus

Bioventus Company Profile

(Free Report)

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.